The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Oral anti-diabetic agents have been associated with adverse cardiovascular events in type 2 diabetes (DM2). We investigated the risk of coronary artery disease (CAD), congestive heart failure (CHF), and mortality using multivariable Cox models in a retrospective cohort of 20,450 DM2 patients from our electronic health record (EHR). We observed no differences in CAD risk among the agents. Metformin was associated with a reduced risk of CHF (HR 0.76, 95% CI 0.64-0.91) and mortality (HR 0.54, 95% CI 0.46-0.64) when compared to sulfonylurea. Pioglitazone was also associated with a lower risk of mortality when compared to sulfonylurea (HR 0.59, 95% CI 0.43-0.81). No other significant differences were found between the oral agents. In conclusions, our results did not identify an increased CAD risk with rosiglitazone in clinical practice. However, the results do reinforce a possible increased risk of adverse events in DM2 patients prescribed sulfonylureas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in the UKPDS, NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research), and ADOPT trials, there were no increased HF signals.127,[562][563][564]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [562]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
(1970) · PubMed · Cited by 976
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., Ali, F., Sholley, C., Worrall, C., & Kelman, J. A. (2010) · JAMA · doi:10.1001/jama.2010.920 · Cited by 512
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Gilbert, R. E., & Krum, H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61402-1 · Cited by 293
Exercise for the management of type 2 diabetes: a review of the evidence
Zanuso, S., Jimenez, A., Pugliese, G., Corigliano, G., & Balducci, S. (2010) · Acta Diabetologica · doi:10.1007/s00592-009-0126-3 · Cited by 282
Gut microbiota and diabetes: from pathogenesis to therapeutic perspective
Burcelin, R., Serino, M., Chabo, C., Blasco-Baque, V., & Amar, J. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0333-6 · Cited by 257
Loke, Y. K., Kwok, C. S., & Singh, S. (2011) · BMJ · doi:10.1136/bmj.d1309 · Cited by 245
Qaseem, A., Barry, M. J., Humphrey, L. L., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m16-1860 · Cited by 207
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
“A number of observational studies investigating the cardiovascular effects of sulfonylureas were likely affected by time-lag bias (12,13,20,25,26,37,42,45,48).”
BackgroundSulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis
Phung, O. J., Schwartzman, E., Allen, R. W., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetic Medicine · doi:10.1111/dme.12232 · Cited by 154
Yu, S., Liao, K. P., Shaw, S. Y., Gainer, V. S., Churchill, S. E., Szolovits, P., Murphy, S. N., Kohane, I. S., & Cai, T. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv034 · Cited by 162
Chronic Disease Risks in Young Adults With Autism Spectrum Disorder: Forewarned Is Forearmed
Tyler, C. V., Schramm, S. C., Karafa, M., Tang, A. S., & Jain, A. K. (2011) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-116.5.371 · Cited by 144
Self-citationMiriovsky, B. J., Shulman, L. N., & Abernethy, A. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8011 · Cited by 159
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 112
Fadini, G. P., Avogaro, A., Esposti, L. D., Russo, P., Saragoni, S., Buda, S., Rosano, G. M. C., Pecorelli, S., & Pani, L. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv301 · Cited by 110
Management of diabetes in older adults
Sesti, G., Antonelli Incalzi, R., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 84
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
Fitchett, D. H., Udell, J. A., & Inzucchi, S. E. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 102
Fidan, E., Ersöz, H. Ö., Yılmaz, M., Yilmaz, H., Koçak, M., Karahan, C., & Erem, C. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0276-y · Cited by 106
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01604.x · Cited by 100
Self-citationCardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 100
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Martino, A. D., Albanese, G., Marfella, R., Sardu, C., et al. (2021) · Biomolecules · doi:10.3390/biom11121834 · Cited by 102
Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes
Shah, D. D., Fonarow, G. C., & Horwich, T. B. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.10.022 · Cited by 100
Bergmark, B. A., Bhatt, D. L., McGuire, D. K., Cahn, A., Mosenzon, O., Steg, P. G., Im, K., Kanevsky, E., Gurmu, Y., Raz, I., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040144 · Cited by 88
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2010) · Diabetes Care · doi:10.2337/dc10-0017 · Cited by 86
Self-citationForst, T., Hanefeld, M., Jacob, S., Moeser, G., Schwenk, G., Pfützner, A., & Haupt, A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112465442 · Cited by 85
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 90
Bell, D. S. H., & Gonçalves, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13652 · Cited by 87
Surrogate-assisted feature extraction for high-throughput phenotyping
Yu, S., Chakrabortty, A., Liao, K. P., Cai, T. A., Ananthakrishnan, A. N., Gainer, V. S., Churchill, S. E., Szolovits, P., Murphy, S. N., Kohane, I. S., et al. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw135 · Cited by 84
Cardioprotective Effects of Metformin
Driver, C., Bamitale, K. O., Kazi, A., Olla, M., Nyane, N. A., & Owira, P. M. O. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000599 · Cited by 87
Fu, A. Z., Johnston, S. S., Ghannam, A., Tsai, K., Cappell, K., Fowler, R., Riehle, E., Cole, A. L., Kalsekar, I., & Sheehan, J. (2016) · Diabetes Care · doi:10.2337/dc15-0764 · Cited by 78
Packer, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 70
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy
Pan, Y., Davis, P. B., Kaebler, D. C., Blankfield, R. P., & Xu, R. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01610-9 · Cited by 69
Observational follow‐up of the PROactive study: a 6‐year update
Erdmann, E., Song, E., Spanheimer, R., van Troostenburg de Bruyn, A. ‐., & Perez, A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12180 · Cited by 65
Bilandzic, A., Fitzpatrick, T., Rosella, L., & Henry, D. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001987 · Cited by 60
IGF-1 and atherothrombosis: relevance to pathophysiology and therapy
Conti, E., Musumeci, B., Giusti, M., Dito, E., Mastromarino, V., Autore, C., & Volpe, M. (2011) · Clinical Science · doi:10.1042/cs20100400 · Cited by 66
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Patorno, E., Patrick, A. R., Garry, E. M., Schneeweiß, S., Gillet, V. G., Bartels, D. B., Massó-González, E. L., & Seeger, J. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3364-z · Cited by 64
Metformin: Nonglycemic Effects and Potential Novel Indications
Anabtawi, A., & Miles, J. M. (2016) · Endocrine Practice · doi:10.4158/ep151145.ra · Cited by 65
Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
Slater, R. E., Strom, J. G., Methawasin, M., Liss, M., Gotthardt, M., Sweitzer, N. K., & Granzier, H. L. M. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201812259 · Cited by 61
The safety of thiazolidinediones
Tolman, K. G. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.534982 · Cited by 53
Butler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 57
Stuart, E. A., DuGoff, E. H., Abrams, M. T., Salkever, D. S., & Steinwachs, D. M. (2013) · eGEMs (Generating Evidence & Methods to improve patient outcomes) · doi:10.13063/2327-9214.1038 · Cited by 55
Effect of glucose-lowering therapies on heart failure
Nassif, M. E., & Kosiborod, M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.211 · Cited by 56
Tseng, C. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011640 · Cited by 51
Kim, Y., Yoon, D., Park, S.-Y., Han, S. J., Kim, D. J., Lee, K. W., Park, R. W., & Kim, H. J. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.003957 · Cited by 48
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 43
Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient
Nantsupawat, T., Wongcharoen, W., Chattipakorn, S. C., & Chattipakorn, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01176-4 · Cited by 42
Epigenetic Therapies for Heart Failure: Current Insights and Future Potential
Napoli, C., Bontempo, P., Palmieri, V., Coscioni, E., Maiello, C., Donatelli, F., & Benincasa, G. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s287082 · Cited by 42
Chang, C., Chang, Y., Lin, J., Chen, S., Chuang, L., & Lai, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2443 · Cited by 41
Metformin and heart failure: never say never again
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.638283 · Cited by 39
“In conclusion, T2DM patients with HF stand to benefit from metformin, and treatment with this agent should -- generally -- not be interrupted because of HF [44-47].”
BackgroundMethodResultInfluentialChang, Y., Chuang, L., Lin, J., Chen, S., Lai, M., & Chang, C. (2015) · Diabetic Medicine · doi:10.1111/dme.12800 · Cited by 37
Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes
Tan, X., & Hu, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1183645 · Cited by 35
Diabetes y enfermedad cardiovascular
Guamán, C., Acosta, W., Alvarez, C., & Hasbum, B. (2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.1.4 · Cited by 35
Effects of Naringin on Cardiomyocytes From a Rodent Model of Type 2 Diabetes
Uryash, A., Mijares, A., Flores, V., Adams, J. A., & Lopez, J. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.719268 · Cited by 35
Use of Metformin in Diseases of Aging
Miles, J. M., Rule, A. D., & Borlaug, B. A. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0490-4 · Cited by 34
Azoulay, L., Schneider‐Lindner, V., Dell’Aniello, S., Schiffrin, A., & Suissa, S. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1834 · Cited by 33
Patorno, E., Garry, E. M., Patrick, A. R., Schneeweiß, S., Gillet, V. G., Zorina, O., Bartels, D. B., & Seeger, J. D. (2015) · Drug Safety · doi:10.1007/s40264-015-0280-1 · Cited by 31
Metformin in heart failure patients
Kinsara, A. J., & Ismail, Y. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.05.009 · Cited by 29
Sportiello, L., Rafaniello, C., Scavone, C., Vitale, C., Rossi, F., & Capuano, A. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.002 · Cited by 27
Pantalone, K. M., Kattan, M. W., Cheng, Y., Wells, B. J., Arrigain, S., Nutter, B., Jain, A., Atreja, A., & Zimmerman, R. S. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03577.x · Cited by 26
Self-citationKannan, S., Pantalone, K. M., Matsuda, S., Wells, B. J., Karafa, M., & Zimmerman, R. S. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12301 · Cited by 25
Self-citationOmarigliptin for the treatment of type 2 diabetes
Tan, X. (2016) · Endocrine · doi:10.1007/s12020-016-1011-9 · Cited by 25
Pioglitazone: beyond glucose control
de Pablos-Velasco, P. L. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.98 · Cited by 24
Nemoto, M., Tajima, N., & Kawamori, R. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0206-4 · Cited by 24
Fadini, G. P., Saragoni, S., Russo, P., Esposti, L. D., de Kreutzenberg, S. V., Melazzini, M. G., Avogaro, A., & on behalf of the OsMed Health DB Network (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12979 · Cited by 23
Chiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
Sciannimanico, S. M., Grimaldi, F., Vescini, F., Pergola, G. D., Iacoviello, M., Licchelli, B., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190507125847 · Cited by 22
Kalra, S. (2011) · PubMed · Cited by 21
Breunig, I. M., Shaya, F. T., McPherson, M. L., & Snitker, S. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.9.895 · Cited by 21
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
Tan, X., Cao, X., Zhou, M., Zou, P., & Hu, J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1360274 · Cited by 18
Krobot, K. J., Ferrante, S. A., Davies, M. J., Seck, T. L., Meininger, G. E., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.703134 · Cited by 21
Simard, P., Presse, N., Roy, L. F., Dorais, M., White‐Guay, B., Räkel, A., & Perreault, S. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017743517 · Cited by 21
Ertek, S., Cicero, A. F. G., Cesur, M., Akçil, M., Kayhan, T., Avcıoğlu, U., & Korkmaz, M. E. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0211-7 · Cited by 19
Woo, V. C., Connelly, K. A., Lin, P., & McFarlane, P. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1576479 · Cited by 18
Bennett, W. L., Balfe, L. M., & Faysal, J. M. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s1-a.1 · Cited by 17
Xu, Y., Wang, T., Yang, Z., Lin, H., Shen, P., & Zhan, S. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5024 · Cited by 17
Bilik, D., McEwen, L. N., Brown, M. B., Selby, J. V., Karter, A. J., Marrero, D. G., Hsiao, V. C., Tseng, C., Mangione, C. M., Lasser, N. L., et al. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1954 · Cited by 17
Baik, S. H., & McDonald, C. J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000940 · Cited by 16
Xu, Z., Zhang, H., Wu, C., Zheng, Y., & Jiang, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.944902 · Cited by 16
Kirk, I. K., Simon, C., Banasik, K., Holm, P. C., Haue, A. D., Jensen, P. B., Jensen, L. J., Rodríguez, C. L., Pedersen, M. K., Eriksson, R., et al. (2019) · eLife · doi:10.7554/elife.44941 · Cited by 15
Revisiting the Diabetes-Heart Failure Connection
Wallner, M., Eaton, D., von Lewinski, D., & Sourij, H. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1116-z · Cited by 14
Blood pressure, Fluid Retention and the Cardiovascular Risk of Drugs
Blankfield, R. P. (2012) · Future Cardiology · doi:10.2217/fca.12.39 · Cited by 12
Asleh, R., Sheikh‐Ahmad, M., Briasoulis, Α., & Kushwaha, S. S. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9666-8 · Cited by 12
Roussel, R., Hadjadj, S., Pasquet, B., Wilson, P. W. F., Smith, S. C., Goto, S., Tubach, F., Marre, M., Porath, A., Krempf, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.04.019 · Cited by 12
Clinical impact of oral antidiabetic medications in heart failure patients
Palazzuoli, A., Ceccarelli, E., Ruocco, G. M., & Nuti, R. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9669-0 · Cited by 12
Cavallari, I., Maddaloni, E., Pieralice, S., Mulè, M. T., Buzzetti, R., Ussia, G. P., Pozzilli, P., & Grigioni, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa427 · Cited by 12
Hussain, A. K. B., Abdelgadir, E., Rashid, F., Alhaj, A., Thadani, P., & Bashier, A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.028 · Cited by 10
Abdin, A., Bauersachs, J., Abdelhamid, M., Aktaa, S., Ghorani, H. A., Bayés‐Genís, A., Biegus, J., Böhm, M., Butler, J., Girerd, N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70087 · Cited by 9
Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study
Luca, M. D., Bosso, G., Valvano, A., Guardasole, V., Botta, A., Carbone, V., Carella, G., Buono, A. D., Giovanni, G. D., Fimiani, B., et al. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02528-4 · Cited by 9
Blankfield, R. P. (2011) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-2010-1369 · Cited by 8
Excess mortality in middle-aged men with diabetes aged 15–34 years at diagnosis
on behalf of the DISS study group, Törn, C., Ingemansson, S., Lindblad, U., & Guðbjörnsdóttir, S. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0272-2 · Cited by 7
Role of Physiotherapy in Managing Type 2 Diabetes Mellitus: A Systematic Review
Kaur, N., & Singh, S. K. (2022) · Journal of Diabetology · doi:10.4103/jod.jod_48_22 · Cited by 6
Is fluid retention a cardiovascular risk factor?
Blankfield, R. P. (2024) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-242128 · Cited by 6
Linee guida ESC 2023 per il trattamento delle malattie cardiovascolari nei pazienti diabetici
Marx, N., Federici, M., Schütt, K. S., Müller‐Wieland, D., Ajjan, R., Antunes, M. J., Christodorescu, R., Crawford, C. A., Angelantonio, E. D., Eliasson, B., et al. (2024) · Giornale Ialiano di Cardiologia · doi:10.1714/4162.41558 · Cited by 6
[Endemic area of paragonimiasis in Vietnam].
Queuche, F., Viên, C. V., & Hà, L. D. (1997) · PubMed · Cited by 6
Terlizzese, P., Losurdo, F., Iacoviello, M., & Aspromonte, N. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9667-7 · Cited by 5
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. L. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00042-8 · Cited by 4
Metadata
- Authors
- Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Pantalone, Kevin M.
- ORCID
- Venue
- Acta Diabetologica
- Published
- 2009-02-05
- Volume
- 46
- Issue
- 2
- Pages
- 145-154
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2020353068
- Cited by
- 123
- References
- 25
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 8 · 2020: 11 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 3 · 2013: 5 · 2012: 8
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- type 2 diabetes, rosiglitazone, pioglitazone, metformin, sulfonylureas, coronary artery disease, congestive heart failure, all-cause mortality, cardiovascular adverse events, oral antidiabetic drugs, drug safety
- MeSH terms
- Rosiglitazone, Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Bypass, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Metformin, Retrospective Studies, Risk Factors, Smoking, Sulfonylurea Compounds, Multivariate Analysis, Proportional Hazards Models, Survival Analysis, Survivors, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.